Needham analyst Mike Cikos maintains GitLab (NASDAQ:GTLB) with a Buy and lowers the price target from $70 to $60.
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: ‘We Were Surprised By Reported Deaths’
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.